The emerging role of immunotherapy in head and neck squamous cell carcinoma (HNSCC): anti-tumor immunity and clinical applications

Panagiota Economopoulou¹, Christos Perisanidis², Evaggelos I. Giotakis³, Amanda Psyrri¹

¹Department of Internal Medicine, Section of Medical Oncology, Attikon University Hospital, National Kapodistrian University of Athens, School of Medicine, Haidari, Athens, Greece; ²Department of Maxillofacial and Oral Surgery, Medical University of Vienna, 1090 Vienna, Austria; ³Department of Otorhinolaryngology, Facial Plastic and Reconstructive Surgery, Städtisches Klinikum Karlsruhe, 76133 Karlsruhe, Germany

Contributions: (I) Conception and design: A Psyrri, P Economopoulou; (II) Administrative support: All authors; (III) Provision of study materials or patients: None; (IV) Collection and assembly of data: P Economopoulou, A Psyrri, EI Giotakis; (V) Data analysis and interpretation: P Economopoulou, A Psyrri, C Perisanidis; (VI) Manuscript writing: All authors; (VII) Final approval of manuscript: All authors.

Correspondence to: Amanda Psyrri, MD, PhD. Attikon University Hospital, Medical School, University of Athens, 1st Rimini, 12462, Haidari, Athens, Greece. Email: dpsyrri@med.uoa.gr.

Abstract: Head and neck squamous cell carcinoma (HNSCC) carries a poor prognosis, with low survival rates for advanced stage tumors and minimal improvement in survival trends through the past decades. It is becoming increasingly clear that HNSCC oncogenesis and evolution is characterized by profound immune defects, as cancer cells evade immunosurveillance due to accumulation of genetic mutations and tumor heterogeneity. Improved understanding of the role of the immune system in cancer has led to the identification of novel therapeutic targets, which are being investigated for their potential to provide durable responses. In this review, we will summarize the role of the immune system in HNSCC, the rationale behind immunotherapy strategies and their clinical applications.

Keywords: Checkpoint inhibitors; head and neck cancer; immune system; immunotherapy

Submitted Mar 15, 2016. Accepted for publication Mar 29, 2016.
doi: 10.21037/atm.2016.03.34

View this article at: http://dx.doi.org/10.21037/atm.2016.03.34

Introduction

Head and neck squamous cell carcinoma (HNSCC) represents a heterogeneous disease entity, which encompasses a variety of tumors originating in the lip/oral cavity, hypopharynx, oropharynx, nasopharynx or larynx with differences in epidemiology, etiology and therapeutics approach. It is the sixth most common malignancy worldwide, accounting for approximately 6% of all cases and is responsible for an estimated 1–2% of all cancer deaths (1).

HNSCC has been historically associated with tobacco and alcohol use; however, in the past decade, infection with high-risk human papillomaviruses (HPV) and especially type 16 has been implicated in the pathogenesis of a subset of HNSCCs, mainly those arising from the oropharynx. HPV-associated oropharyngeal cancer represents a distinct biological and clinical entity with a more favorable prognosis (2,3). This raises the question whether HPV positive patients should be treated with less intensive treatment, which is currently being addressed in clinical trials. The majority of HNSCC patients present with locally advanced disease for which multimodality therapeutic approach is employed. For recurrent/metastatic (R/M) disease, cytotoxic-based chemotherapy remains the standard therapeutic option and the median survival of patients treated with palliative chemotherapy alone ranges from 6 to 10 months (4).

Low survival rates in combination with significant toxicities caused by current treatment strategies used in HNSCC underlines the urgent need for enhanced treatment options. It has been widely accepted that the
immune system plays a crucial role in cancer development, as tumor cells evade immunosurveillance by exploiting inhibitory checkpoint pathways that suppress antitumor T-cell responses (5). HNSCC has been intensely studied as an immunosuppressive disease. Following the increasing understanding of the underlying mechanisms behind control of malignancies by the immune system, the establishment of immune-based therapies has emerged as a promising approach for the treatment of cancer.

In this review, we will focus on the role of immune system in HNSCC tumorigenesis and describe immunotherapy approaches currently under investigation.

**Immune system and cancer development**

Cancer is a multistep process originating from genetic alterations in normal proliferation and differentiation. In a normally functioning environment, immune surveillance acts as an effective tumor suppressor mechanism, as these alterations trigger the development of tumor-related antigens initially recognized by the immune system. However, it is believed that after this equilibrium phase, immune system might lose the ability to eradicate cancer cells, or new mutations might render tumor cells poorly immunogenic and resistant to elimination by immune cells (6-8).

Both the innate and adaptive immune systems have the ability to distinguish between self and non-self pathogens. Innate immunity is based on non-specific defense mechanisms that are activated immediately after contact with pathogen; it uses a limited number of receptors that are encoded in the germline and are able to recognize features common to many pathogens. In contrast, adaptive immunity relies upon somatic cell gene rearrangements to produce a multitude of antigen receptors that discriminate between closely related molecules; it is mainly driven by highly specific antigen receptors on T and B cells and is highly specific to a particular pathogen (9).

The immune system can identify and eliminate tumor cells based on their expression of tumor-associated antigens (TAA) via a process termed immunosurveillance. Tumors can express microbial proteins, mutated proteins, and fusion proteins. The immune system can also recognize aberrantly expressed self proteins (10). During tumor evolution, T-cells are activated upon encounters with antigen-presenting cells (APC), usually dendritic cells (DC), B-cells or macrophages that display TAA, which are bound to major histocompatibility complex proteins (MHC) and interact with T-cell receptors (TCRs). A complex network of co-stimulatory and co-inhibitory pathways that normally play a pivotal role in the prevention of autoimmunity, are manipulated by cancer cells to escape immunosurveillance. Co-stimulatory or activating receptors include CD28, CD137, CD40, and OX-40 (11). Upon secretion of specific chemokines, a proportion of T-cells differentiate into cytotoxic CD8+ cells that move to the tumor microenvironment and directly attack tumor cells. Using gene expression profiling, studies initially conducted in malignant melanoma have led to identification and description of two separate subtypes of tumor microenvironment based on the presence of a transcriptional profile denotative of T cell infiltration (12). More specifically, "inflamed" tumor immunophenotype is characterized by recruitment of T-cells, immune signals and chemokines, whereas "non-inflamed" tumor phenotype lacks spontaneous infiltration of T-cells and other immunomodulators. Most importantly, it is suggested that in the subset of patients sharing the "inflamed phenotype" tumor progression might be a result of negative immune regulators acting at the level of the microenvironment. On the contrary, failure in "non-inflamed" tumors is attributed to poor effector T cell trafficking at the site of the tumor (13,14).

**The role of immune system in head and neck cancer development and progression**

Emerging evidence supports a vital role of the immune system in the development and evolution of HNSCC. Furthermore, the status of the immune system is likely to be of prognostic value in HNSCC. HNSCC is considered an immunosuppressive disease, characterized by dysregulation of immunocompetent cells and impaired cytokine excretion (15). Immunosuppressive individuals are prone to develop head and neck cancer and prognosis is poor (16). For HPV(−) HNSCC, although there is a strong causative association with tobacco and alcohol, it is hypothesized that tumor progression reflects the inability of the immune system to eliminate the cancer. As various cells of the immune system provide a complex network of defense, the balance between subsets of T-lymphocytes, combined with the effect of tumor microenvironment, are believed to modulate antitumor immunity (17). T-cells, macrophages, dendritic and natural killers (NK) cells are important players in the tumor microenvironment, whose functional alterations modify immune response.

Patients with HNSCC have reduced antitumor immune responses, and tumor progression or relapse is believed to be
studies have demonstrated an increased population of CD8+ lymphocytes, Tregs and increased CD8+/Treg ratio in HPV+ OPC, which are associated with improved prognosis (31,32).

The cancer stem cell hypothesis supports the notion that in a heterogenic tumor, a subpopulation of tumor cells (cancer stem cells-CSCs) is capable of initiating and expanding a tumor (33). In HNSCC, it has been proposed that slow growing CSCs evade conventional therapies and regenerate the tumor, accounting for the high rates of recurrence (34). Emerging evidence suggests that host immune system has the ability to recognize CSCs and provoke an immune response. Early studies in HNSCC have shown that NK cells may preferably target CSCs (35). In addition, CSCs interact with tumor microenvironment. In HPV-related HNSCC, the presence of CSCs is controversial (36-38). Interestingly, CSCs have been associated with radioresistance and cisplatin-resistance in HNSCC (39,40).

Although immunoediting may eliminate tumor cells with alterations in their antigenic epitope profile, many immunoresistant variants escape from the immune system of the host by immunosuppressive molecular and cellular mechanisms. Therefore, tumors may avoid elimination by the immune system through outgrowth of tumor cells that can suppress, disrupt, or escape the immune system.

In HNSCC, the dominant mechanism of immune-escape is inhibition of tumor antigen presentation. Disruption of antigen presentation can occur by (I) down-regulation or loss of tumor human leukocyte antigen (HLA) class I molecules expression; (II) disruption of proteins involved in antigen processing, such as TAP1, LMP2, LMP7; and (III) suppression of APC function and maturation (10,41). Large scale next generation sequencing of HNSCC has revealed several mutations in HLA alleles and APC components, but tumor cells avoid complete loss of HLA expression, as it leads to recognition by NK cells (42). It has been also proposed that signal transducer and activator of transcription (STAT) family of proteins controls defects in APC, as well as APC function. For instance, deficiency of activated STAT1 results in reduced expression of APC components, while aberrant signaling of STAT3 contributes to impaired tumor antigen presentation by DCs (43,44). Nevertheless, disruption of TAA presentation results in functionally defective circulating lymphocytes that have enhanced levels of apoptosis and increased suppression induced by Tregs (45).

Second, the tumor microenvironment contains various immunosuppressive factors from different sources that tumors use as defense mechanisms against the immune...
Immune checkpoints, such as PD-1 pathway, are part of a protein-ligand receptor system that controls T-cell activation. They are critical for protecting self-tolerance and modulating the duration and amplitude of physiologic immune response, but are manipulated by cancer to permit tumor growth that is unchecked by the immune system. In a normal cell, when PD-L1 or PD-L2 binds to PD-1, the T cell becomes inactive. This is a way that the body regulates the immune system, to avoid an overreaction. However, PD-L1 is also expressed in HNSCC, resulting in disarming of T cells after binding to PD-1 on T cells (56). The concentration of TILs is inversely associated with PD-L1 expression of tumor cells (57). CTLA-4 is another immune checkpoint located on the surface of activated CTLs that binds to the B7 ligands found on APCs. T-cells have a CD28 receptor that represents a stimulatory counterpart to CTLA4, causing T-cell activation. CTLA-4 competes with CD28 receptor for binding to the B7 ligand resulting in either an inhibitory or stimulatory effect on T-cells (11).

### Immunotherapeutic strategies for HPV-induced HNSCC

HPV-associated HNSCC represents a subset of OPC patients with unique characteristics that might require less intensive treatment than their tobacco-induced counterparts. Improvement in survival is independent of available conventional treatments and there is a concern of unnecessary toxicity. It has been suggested that clinical trials should discriminate between HPV(+) and HPV(–) patients. HPV-targeted immunotherapy represents a therapeutic approach that might allow clinicians to use conventional treatment at lower doses, reducing treatment-related toxicity. Viral oncoproteins E6 and E7 represent good targets for immunotherapy, as they are continuously expressed by tumor cells and are essential to maintain the transformation status of HPV+ oropharyngeal cancer cells (2).

The primary goal of prophylactic vaccination is to induce an immune response such that high-titers of HPV-neutralizing antibodies are produced that are capable of preventing initial infections, making HPV antigen-specific B cells the target cell type for these vaccines. On the contrary, therapeutic vaccines focus on the generation of CD8+ HPV-specific T cell immune response. E6 and E7 oncoproteins are most frequently targeted for vaccine development (58).

Vaccine mediated immune strategies are either prophylactic against primary infection with the view to prevent carcinogenesis or therapeutic in established HPV-
associated HNSCC targeting E6 and E7 oncoproteins. HPV preventive vaccines are based on virus-like particles assembled from recombinant HPV protein and contain inactive L1 capsid proteins; they act by eliciting virus-neutralizing antibody responses that prevent initial infection (59). Gardasil (Merck) and Cervarix (GlaxoSmithKline) are two commercially available HPV vaccines shown to be effective for cervical carcinoma in large randomized trials (60). Their role in prevention of HPV-related oropharyngeal cancers is currently being evaluated, with one trial showing promising results (61). A trial testing efficacy of Gardasil in 11-year-old boys in Mexico City is underway (NCT02382900). Of note, due to loss of L1 expression after established HPV infection, preventive vaccines are not effective in HPV-related HNSCC.

Several vaccination therapies are under investigation in HPV-associated HNSCC. DNA vaccines produce non-living antigens able to induce CTL, Th and B cell immunity. Their benefits include safety, low cost and easy production (62). Multiple DNA vaccine trials targeting HPV are being tested in cervical cancer. A phase I trial is currently assessing safety and feasibility of administration of pNGVL4a-CRT/E7 (Detox) DNA Vaccine in combination with cyclophosphamide in HPV+ OPC (NCT01493154). Vaccine pNGVL4a-CRT/E7 consists of the DNA plasmid pNGVL4a-A encoding calreticulin, linked to a detox form of human papillomavirus (HPV) type 16 E7 antigen. On the other hand, peptide vaccines incorporate amino acid sequences that are synthesized to form an immunogenic peptide molecule representing the specific epitope of a TTA that binds onto HLA. After activation of CTLs by the peptide vaccine, cells can recognize peptide-MHC I complex on tumor cells (63). Several peptide vaccines are under evaluation in HPV+ HNSCC. In a phase I trial, five patients with advanced HNSCC were treated with peptide vaccines composed of HLA-I and HLA-II restricted melanoma antigen E (MAGE)-A3 or HPV-16 derived peptides, provoking a measurable immune response and acceptable toxicity (64). Furthermore, a phase II trial evaluating the efficacy of HPV16 E6 and E7 peptide vaccines in patients with HPV-related tumors including HNSCC has been completed and results are expected shortly (NCT00019110).

Vaccination strategies involving DCs are currently being assessed in HPV+ HNSCC. DC vaccines are produced by culturing ex vivo DCs that have been derived from patients with the HPV antigen; after maturation and activation, DCs cells are injected back into the patient (42). A phase I trial testing the safety and efficacy of intratumoral injection of a DC vaccine in patients with advanced HNSCC has been unfortunately withdrawn (NCT00492947). On the other hand, several bacterial HPV vaccines targeting E6 and E7 have been developed. Sewell et al. showed that in an HPV 16 transfected mouse model, mice that were vaccinated with Listeria based anti E7 vaccine experienced a substantial reduction in tumor size (65). Interestingly, an ongoing clinical study evaluates the efficacy of neoadjuvant listeria-based HPV vaccine ADX11-001 in patients with HPV+ HNSCC stage I–IV undergoing robot-assisted surgery (NCT02002182).

Finally, adoptive T-cell transfer (ACT) might be a promising immunotherapy strategy for HPV HNSCC; it involves harvesting and ex vivo expansion of the patient’s own tumor antigen specific T-cells. Subsequently, T-cells are re-introduced to the patient, with the view to enhance immunity and improve antitumor immune response (66). An ongoing phase II clinical trial is assessing the efficacy of lymphodepletion followed by autologous infusion of TILs in patients with HPV+ advanced solid tumors including OPC (NCT01585428).

Immunotherapeutic strategies for HPV(–) HNSCC

Improved understanding of the role of the immune system in cancer has led to the identification of a range of novel therapeutic targets. Immuno-oncology is an evolving field of investigation that includes active immunotherapies that are designed to target and harness the patient’s own immune system directly to fight cancer. More specifically, it is designed to leverage the unique properties of the immune system (specificity, adaptability, and memory). The primary goal of immunotherapy is to shift the balance in favor of an immune response against the tumor, allowing tumor eradication or long-term suppression of tumor growth, and the generation of immunological memory.

Monoclonal antibodies

Cetuximab is a chimeric immunoglobulin G1 (IgG1) monoclonal antibody that has been approved by the US Food and Drug Administration (FDA) in combination with chemotherapy as the standard first line treatment for R/M HNSCC. It is also used in conjunction with radiation for locally advanced HNSCC (67,68). Cetuximab efficacy is mediated by antibody-dependent cell mediated cytotoxicity (ADCC), a mechanism of cell-mediated immune defense
whereby NK cells, actively lyse a target cell, whose membrane-surface antigen has been bound by cetuximab. NK cells are activated upon binding to surface receptor FCγRIIIa (69). Furthermore, cetuximab provokes CTL antitumor response through cross-priming of DCs and NKs (46). Other anti-EGFR monoclonal antibodies currently evaluated in HNSCC include panitumumab, nimotuzumab and zalutumumab. Among them, panitumumab has produced modest results when added to platinum based chemotherapy in patients with R/M HNSCC (70). Zalutumumab has demonstrated an OS of 5.3 months and a PFS of 2.1 when administered as monotherapy in patients with platinum refractory R/M HNSCC (71). Finally, nimotuzumab in combination with (chemo) radiation in locally advanced HNSCC has shown a survival benefit in tumors overexpressing EGFR (72).

**Immune checkpoint inhibitors**

It is now clear that tumors co-opt certain immune-checkpoint pathways as a major mechanism of immune resistance, particularly against T cells that are specific for tumor antigens. Because many of the immune checkpoints are initiated by ligand-receptor interactions, they can be readily blocked by antibodies or modulated by recombinant forms of ligands or receptors. Ipilimumab, a mAb against CTLA-4 that has received FDA approval for metastatic melanoma, is currently being evaluated in clinical trials in combination with cetuximab and intensity-modulated radiotherapy (IMRT) in patients with advanced HNSCC (NCT01860430 and NCT01935921). A phase 1, open-label, dose escalation study of MGA271 (enoblituzumab, a humanized mAb against CD276 (B7-H3) in combination with ipilimumab in patients with B7-H3-expressing HNSCC and other solid tumors) is also ongoing (NCT02381314). Tremelimumab is another anti-CTLA4 antibody currently being assessed in clinical trials.

PD-1 interacts with two ligands; PD-L1, that is expressed mainly on tumor cells and other immune cells and PD-L2, which is expressed primarily on macrophages and DCs. Anti-PD-1 antibody pembrolizumab (MK-3475) has shown promising results in HNSCC. Preliminary results from KEYNOTE-012, a phase I assessing the efficacy of pembrolizumab in patients with R/M HNSCC had shown a response rate of 20% in PD-L1 positive tumors. Interestingly, 78% were found to be PD-L1-positive. Responses were observed in both HPV+ and HPV− patients, but overall survival was better in HPV+ patients.

Response duration ranged from 8 to 41 weeks. PD-L1 expression was positively associated with ORR (P=0.018) and PFS (P=0.024). A larger HNSCC expansion cohort of KEYNOTE-012 was recently presented in the 2015 ASCO meeting, demonstrating an overall response rate (ORR) of 18.2%, whereas 31.3% of patients had stable disease; response rates were similar in HPV+ and HPV− HNSCC. Toxicity was tolerable, with 7.6% of patients experiencing > grade 3 drug-related events (73). Pembrolizumab is further assessed in multiple clinical settings in HNSCC. In KEYNOTE-048, it is evaluated either as monotherapy or in combination with chemotherapy versus standard chemotherapy in patients with R/M HNSCC in the first line setting (NCT02358031). In KEYNOTE-040, pembrolizumab is compared to chemotherapy or cetuximab in the second line setting (NCT02252042). Pembrolizumab is also currently evaluated in combination with re-irradiation and as part of primary treatment in various clinical trials (NCT02289209, NCT02296684). Anti-PD-1 Abs nivolumab (NCT02105636; n=340 patients) and pembrolizumab (NCT02358031; n=750 patients) are being evaluated as a single agents in randomized phase III trials for platinum-refractory HNSCC. More specifically, checkmate-141 phase III trial assessed the efficacy of nivolumab versus physician's choice (cetuximab, methotrexate, or docetaxel) in platinum refractory disease. The study was terminated early after an independent monitoring panel determined the primary endpoint of improvement in OS was met with nivolumab. Another promising anti PD-L1 antibody is durvalumab (MEDI4736), which has shown promising results (~14% response rate as per RECIST criteria, with 24% response rate in PD-L1+ patients) in a phase I trial (74). A phase III trial evaluating durvalumab alone or in conjunction with tremelimumab compared to standard treatment is under way in patients with advanced HNSCC (NCT02369874).

Another group of receptors with a modulating effect on immune cells includes other checkpoint receptors such as LAG-3 or the killer-cell immunoglobulin-like receptors (KIRs) (75). They regulate immune response via interaction with MHC I molecules. Most of the receptors suppress cytotoxicity, mainly by turning off NK cells when HLA is expressed on tumor cells. Ongoing trials are testing an anti-KIR moAb in combination with ipilimumab (NCT01750580) or nivolumab (NCT01714739). Anti-PD-1 monoclonal antibodies are also being studied in various novel combinations in phase I setting, such as nivolumab plus agonistic anti-CD137 moAbs.
(urelumab, NCT02253992), nivolumab plus anti-LAG-3 (NCT01968109), and cetuximab plus urelumab.

**DC vaccines**

DC vaccines have received considerable interest due to their capacity of inducing a robust immunity reaction. As described before, they are manufactured via isolation of DCs and loading of tumor antigen *ex vivo*, followed by reintroduction of DCs into the patients as a cellular vaccine, usually into the tumor or into lymphnodes. In a preclinical study, a DC vaccine was developed using a skin flap transfer treated with sensitized DCs in a rat tumor model. It was observed that the DC-treated group showed a reduction in tumor size and an immunological response, defined as elevated levels of IL-2 and IFN-γ (76). A phase I trial has been conducted in stage I–IVA patients with HNSCC with no active disease using a DC vaccine loaded with two HLA-A*0201-restricted T cell-defined p53 peptides alone, plus either a wt p53 helper peptide or nonspecific helper peptide derived from tetanus toxoid. In this study, disease-free survival was 88% and p53-specific T cell frequencies were increased in approximately 70% of patients, whereas toxicity was acceptable (77). Finally, in another study, autologous DCs loaded with apoptotic tumor cells were injected intranodally in patients with advanced HNSCC; immunological responses were satisfactory and all patients were long term survivors (78).

**Adoptive T cell therapy (ACT)**

As previously described, ACT is a therapeutic procedure where T cells are isolated from peripheral blood mononuclear cells of patients or from TILs of primary tumor, undergo *in vitro* expansion and are re-infused into the patient, with the view to enhance anti-tumor immune response. Genetic engineering of T cells before re-introduction potentially augments function through several autonomous mechanisms. In a phase I study conducted in 17 patients with R/M HNSCC, patients were vaccinated on the thigh with irradiated autologous tumor cells; subsequently, T-cells derived from resected inguinal lymphnodes were expanded *in vitro* and re-introduced into the patients. Among the patients enrolled, 6/17 patients experienced disease control (79). Importantly, efficacy of ACT is enhanced by cytotoxic chemotherapy. In a retrospective study, ACT was added as experimental therapy in patients with resectable HNSCC receiving induction chemotherapy. Interestingly, median OS and PFs were improved in patients treated with ACT (80). Finally, ACT has been assessed in patients with R/M nasopharyngeal carcinoma. In a phase II study, ACT with EBV-specific CTLs in combination with chemotherapy has shown promising results, demonstrating a 2-year OS of 62.9% (81).

**Combination of immunotherapies**

The combination of immunotherapeutic strategies represents a challenging approach, with a view to enhance antitumor immunity by targeting several aspects of immune response. In malignant melanoma, the combination regimen of anti-PD-1 antibody nivolumab and anti-CTL4 antibody ipilimumab has been approved by the FDA after yielding promising results in a phase III trial. A phase III study (KESTREL) is evaluating concurrent tremelimumab and durvalumab vs. durvalumab monotherapy vs. standard of care (EXTREME) as first-line treatment in patients with recurrent and/or metastatic HNSCC. This promising clinical trial design combining two immune checkpoint inhibitors aims to produce deep and durable antitumor responses, which thus far have been observed in only a minority of patients with monotherapy approaches. The phase I, open label, dose-escalation and expansion study evaluating durvalumab and tremelimumab in advanced solid tumors showed a 27% response rate (95% CI, 13–46) in PD-L1 negative patients, with a disease control rate of 48% (95% CI, 31–66) at ≥16 weeks after therapy. Notably, anti-PD1/anti-PD-L1 monotherapy yields an approximately 5–10% response rate in PD-L1 negative patients; therefore, the addition of low-dose anti-CTLA-4 may benefit these patients.

**Conclusions and future directions**

HNSCC represents a heterogeneous group of diseases. To date, conventional treatment has mediocre results and prognosis in patients with advanced disease is dismal. There is a growing body of evidence that the immune system plays a pivotal role in oncogenesis and tumor evolution; immunoediting is the term used to describe the immune system’s protective role against cancer development. Genetic and epigenetic alterations that are characteristic of all cancers provide a diverse set of antigens that the immune system can use to distinguish tumor cells from their normal counterparts. However, tumors have the capacity to
### Table 1 Immunotherapy studies in HNSCC

<table>
<thead>
<tr>
<th>Trial NCT/name</th>
<th>N of pts</th>
<th>Phase</th>
<th>Stage/eligibility</th>
<th>Treatment</th>
<th>Primary endpoint</th>
<th>Status</th>
</tr>
</thead>
<tbody>
<tr>
<td>Anti-PD-1</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>NCT02586207</td>
<td>39</td>
<td>Ib</td>
<td>Stage III-IV (non metastatic) HNSCC</td>
<td>Pembrolizumab + weekly cisplatin + RT</td>
<td>AEs</td>
<td>Recruiting</td>
</tr>
<tr>
<td>NCT02609503</td>
<td>29</td>
<td>II</td>
<td>Stage III-IV (non metastatic) HNSCC</td>
<td>Pembrolizumab + IMRT</td>
<td>PFS at 20 weeks</td>
<td>Pending activation</td>
</tr>
<tr>
<td>RTOG3504</td>
<td>185</td>
<td>I/II</td>
<td>Advanced OPC</td>
<td>IMRT + cetuximab (HPV+) or cisplatin (HPV-) + PFS nivolumab</td>
<td>PFS</td>
<td>In development</td>
</tr>
<tr>
<td>KEYNOTE-012</td>
<td>224</td>
<td>I</td>
<td>Solid tumors (including a HNSCC cohort)</td>
<td>Pembrolizumab 10 mg/kg q2w</td>
<td>ORR, safety</td>
<td>Accrual completed</td>
</tr>
<tr>
<td>KEYNOTE-040</td>
<td>446</td>
<td>III</td>
<td>Platinum refractory HNSCC</td>
<td>Pembrolizumab vs. cetuximab, methotrexate or docetaxel</td>
<td>PFS, OS</td>
<td>Recruiting</td>
</tr>
<tr>
<td>KEYNOTE-055</td>
<td>150</td>
<td>II</td>
<td>Platinum&amp; cetuximab refractory HNSCC</td>
<td>Pembrolizumab</td>
<td>ORR, AEs</td>
<td>Recruiting</td>
</tr>
<tr>
<td>KEYNOTE-048</td>
<td>750</td>
<td>III</td>
<td>R/M HNSCC, first line, &gt;6 months from curative therapy</td>
<td>Pembrolizumab vs. pembrolizumab + platinum/5-FU vs. cetuximab + platinum/5-FU</td>
<td>PFS</td>
<td>Recruiting</td>
</tr>
<tr>
<td>NCT02289209</td>
<td>48</td>
<td>II</td>
<td>Locoregional relapse/2nd primary</td>
<td>Reirradiation + pembrolizumab</td>
<td>PFS</td>
<td>Recruiting</td>
</tr>
<tr>
<td>CHECKMATE 141</td>
<td>360</td>
<td>III</td>
<td>Platinum refractory HNSCC (progression or relapse &lt;6 months of last platinum dose)</td>
<td>Nivolumab vs. cetuximab or methotrexate or docetaxel</td>
<td>OS at 28 months</td>
<td>Accrual completed</td>
</tr>
<tr>
<td>Anti-PD-1 and CD137 agonist</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>NCT02253992</td>
<td>200</td>
<td>I</td>
<td>Multiple tumors, including HNSCC</td>
<td>Nivolumab + urelumab</td>
<td>ORR, safety</td>
<td>Recruiting</td>
</tr>
<tr>
<td>Anti-PD-1 and vaccine</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>NCT02426892</td>
<td>28</td>
<td>II</td>
<td>HPV-16 + advanced solid tumors including OPC</td>
<td>Nivolumab + ISA-101</td>
<td>ORR at 11 weeks</td>
<td>Not yet recruiting</td>
</tr>
<tr>
<td>NCT02291055</td>
<td>66</td>
<td>I/II</td>
<td>R/M cervical or HNSCC, ≤3 lines of therapy</td>
<td>ADXS11-001 vs. durvalumab vs. ADXS11-001 + PFS at 2 years, AEs</td>
<td>Durvalumab</td>
<td>Active, not recruiting</td>
</tr>
<tr>
<td>Anti-PD-L1</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>NCT01693562</td>
<td>1,038</td>
<td>I/II</td>
<td>Advanced solid tumors including HNSCC</td>
<td>Durvalumab (MEDI4736)</td>
<td>ORR, AEs</td>
<td>Recruiting</td>
</tr>
<tr>
<td>HAWK</td>
<td>112</td>
<td>II</td>
<td>Platinum refractory HNSCC</td>
<td>Durvalumab in PD-L1+</td>
<td>ORR, AEs</td>
<td>Recruiting</td>
</tr>
<tr>
<td>NCT02554812</td>
<td>147</td>
<td>I/II</td>
<td>Advanced solid tumors (HNSCC cohort)</td>
<td>Avelumab + PF-05082566</td>
<td>ORR, AEs</td>
<td>Recruiting</td>
</tr>
<tr>
<td>Anti-PD-L1 and anti-CTL4</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>CONDOR</td>
<td>240</td>
<td>II</td>
<td>Platinum refractory R/M HNSCC, PD-L1 negative</td>
<td>Durvalumab vs. tremelimumab vs. durvalumab + tremelimumab</td>
<td>ORR</td>
<td>Recruiting</td>
</tr>
<tr>
<td>EAGLE</td>
<td>720</td>
<td>III</td>
<td>Platinum refractory R/M HNSCC &lt;6 months from therapy containing platinum PD-L1+ or –</td>
<td>Durvalumab vs. durvalumab + tremelimumab vs. standard of care</td>
<td>PFS, OS</td>
<td>Recruiting</td>
</tr>
</tbody>
</table>

Table 1 (continued)
Table 1 (continued)

<table>
<thead>
<tr>
<th>Trial NCT/name</th>
<th>N of pts</th>
<th>Phase</th>
<th>Stage/eligibility</th>
<th>Treatment</th>
<th>Primary endpoint</th>
<th>Status</th>
</tr>
</thead>
<tbody>
<tr>
<td>KESTREL</td>
<td>628</td>
<td>III</td>
<td>R/M HNSCC first line</td>
<td>Durvalumab vs. durvalumab + tremelimumab vs. cetuximab/platinum/5-FU</td>
<td>PFS, OS</td>
<td>Recruiting</td>
</tr>
</tbody>
</table>

Anti-CTL4

| NCT01860430  | 18       | I     | Stage III–IV HNSCC, p16– or intermediate risk p16+ | Cetuximab + IMRT + ipilimumab | Safety | Recruiting       |

CD137 agonist

| NCT02110082 | 104      | I     | Advanced/metastatic, HNSCC or CRC | Urelumab + cetuximab | ORR, AEs | Recruiting       |

Vaccine

| NCT02526316 | 10       | I     | Advanced HPV+ cancers | P16_37-63 peptide plus Montanide ISA-51 + cisplatin-based chemotherapy | Immune response against peptide P16_37-63 | Recruiting       |
| NCT01462838 | 26       | I/II  | Advanced HPV-induced cancers | P16_37-63 peptide plus Montanide ISA-51 | Immune response against peptide P16_37-63 | Accrual completed |
| NCT02544880 | 54       | I/II  | Stage III/IV recurrent or 2nd primary HNSCC | Tadalafil + anti-MUC1 vaccine + anti-influenza vaccine | AEs, tumor-specific immune response | Not yet recruiting |
| NCT02002182 | 30       | II    | T1–3 N0–2b OPC, HPV+ | ADXS11-001 followed by transoral robotic surgery | change in HPV E6/ E7-specific CD8+ CTL responses | Recruiting       |

Adoptive T-cell therapy

| NCT01585428 | 73       | II    | HPV-associated cancers | Fludarabine + cyclophosphamide followed by TILs and adesleukin | ORR | Recruiting       |

AE, adverse event; CTL, cytotoxic T lymphocyte; CTL-4, cytotoxic T lymphocyte-associated protein 4; FU, fluorouracil; HNSCC, head and neck squamous cell carcinoma; HPV, human papillomavirus; IL, interleukin; IMRT, intensity-modulated radiation therapy; MUC-1, mucin-1, cell surface associated; OPC, oropharyngeal cancer; ORR, overall response rate; OS, overall survival; PD-1, programmed death-1; PD-L1, programmed death-1 ligand; PFS, progression-free survival; R/M, recurrent/metastatic; RT, radiotherapy; TILs, tumor-infiltrating lymphocytes.
manipulate the immune system in their favor. Our better understanding of the mechanisms of immune escape has led to the development of novel immunotherapies that has shown initial promising results in many solid tumors including HNSCC. A plethora of novel strategies is being explored in clinical trials with the view to improve patient outcome.

Acknowledgements
None.

Footnote
Conflicts of Interest: The authors have no conflicts of interest to declare.

References


Cite this article as: Economopoulou P, Perisanidis C, Giotakis EI, Psyrri A. The emerging role of immunotherapy in head and neck squamous cell carcinoma (HNSCC): anti-tumor immunity and clinical applications. Ann Transl Med 2016;4(9):173. doi: 10.21037/atm.2016.03.34